Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19

Anar, Mahsa Asadi; Foroughi, Elaheh; Sohrabi, Elika; Peiravi, Samira; Tavakoli, Yasaman; Khouzani, Mozhgan Kameli; Behshood, Parisa; Shamshiri, Melika; Faridzadeh, Arezoo; Keylani, Kimia; Langari, Seyedeh Faride; Ansari, Akram; Khalaji, Amirmohammad; Garousi, Setareh; Mottahedi, Mehran; Honari, Sara; Deravi, Niloofar

doi:10.3389/fphar.2022.1036093

Cited by 2 publications

(1 citation statement)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new, promising perspective for COVID-19 therapy is a combination of anticoagulants and antidepressant drugs (selective serotonin reuptake inhibitors—SSRIs). SSRIs have proven beneficial in the treatment of SARS-CoV-2 infection, by preventing cytokine release [ 130 ].…”

Section: Discussionmentioning

confidence: 99%

The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases

Szilveszter¹,

Pál

Simon-Szabó

et al. 2023

IJMS

View full text Add to dashboard Cite

The course of COVID-19 is highly dependent on the associated cardiometabolic comorbidities of the patient, which worsen the prognosis of coronavirus infection, mainly due to systemic inflammation, endothelium dysfunction, and thrombosis. A search on the recent medical literature was performed in five languages, using the PubMed, Embase, Cochrane, and Google Scholar databases, for the review of data regarding the management of patients with a high risk for severe COVID-19, focusing on the associated coagulopathy. Special features of COVID-19 management are presented, based on the underlying conditions (obesity, diabetes mellitus, and cardiovascular diseases), emphasizing the necessity of a modern, holistic approach to thromboembolic states. The latest findings regarding the most efficient therapeutic approaches are included in the article, offering guidance for medical professionals in severe, complicated cases of SARS-CoV-2 infection. We can conclude that severe COVID-19 is closely related to vascular inflammation and intense cytokine release leading to hemostasis disorders. Overweight, hyperglycemia, cardiovascular diseases, and old age are important risk factors for severe outcomes of coronavirus infection, involving a hypercoagulable state. Early diagnosis and proper therapy in complicated SARS-CoV-2-infected cases could reduce mortality and the need for intensive care during hospitalization in patients with cardiometabolic comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases

Szilveszter¹,

Pál

Simon-Szabó

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Systemic inflammation and quality of life in patients with coronavirus disease: interrelation features

Pavlovskyi,

Vozniuk

2024

Wiad Lek

View full text Add to dashboard Cite

Aim: To characterize the features of the interrelation of systemic inflammation with the quality of life of patients with coronary virus disease. Materials and Methods: 30 patients were examined 1 month after inpatient treatment for COVID-19. Quality of life (QoL) of patients was determined according to the questionnaire Medical Outcomes Study – 36-item Short Form (SF-36). The glucose level, circulating immune complexes (CICs), concentration of immunoglobulin (Ig) A, interleukin (IL)-8 and IL-33 levels were determined in the blood serum of patients. Results: QoL of patients after coronavirus disease is significantly deteriorated: patients note a significant limitation in physical functioning, pain perception, vitality, role-physical and social functioning and mental health. The increase in glycemia and glycated hemoglobin levels in post-COVID-19 patients was significantly associated with the deterioration of patients` general health (GH) (r = −0,228; (p=0,040) and (r = −0,280; (p=0,014), respectively). The IL-33 concentration in such patients correlated directly with role-physical functioning (RP) (r = 0,385; p=0,029). The CICs level decline was associated with deterioration of RP (r = 0,227; p=0,042) and GH (r = 0,227; p=0,041). Conclusions: The study of clinical-functional, biochemical, immunological and psychological indicators, quality of life, and their mutual influences should be included in the development of the program for the diagnosis, treatment, and rehabilitation of patients after the transfer of COVID-19 at the outpatient stage of treatment by doctors of general practice-family medicine.

show abstract

Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19

Cited by 2 publications

References 150 publications

The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases

The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases

Systemic inflammation and quality of life in patients with coronavirus disease: interrelation features

Contact Info

Product

Resources

About